menu
    • menu
    [{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Triptorelin Pamoate","moa":"GnRH analog","graph1":"Oncology","graph2":"Approved","graph3":"Verity Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verity Pharmaceuticals Inc \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Verity Pharmaceuticals Inc \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin: Strain Russian BCG-I","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Verity Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Verity Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verity Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Testosterone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Verity Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Granisetron","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Verity Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verity Pharmaceuticals Inc \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Verity Pharmaceuticals Inc \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Lipocine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Verity Pharmaceuticals Inc","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.27000000000000002,"dosageForm":"Capsule","sponsorNew":"Verity Pharmaceuticals Inc \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Verity Pharmaceuticals Inc \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Lipocine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Verity Pharmaceuticals Inc","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.27000000000000002,"dosageForm":"Capsule","sponsorNew":"Verity Pharmaceuticals Inc \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Verity Pharmaceuticals Inc \/ Verity Pharmaceuticals Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Verity Pharmaceuticals Inc

    Menu

    Verity Pharmaceuticals Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone Undecanoate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Lipocine

                            Deal Size : $270.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lipocine Announces Continued Commercialization of TLANDO® Through Verity Pharmaceuticals

                            Details : Verity will market TLANDO (testosterone undecanoate), the only oral testosterone replacement therapy indicated for conditions associated with endogenous testosterone deficiency in adult males.

                            Product Name : Tlando

                            Product Type : Small molecule

                            Upfront Cash : $2.5 million

                            February 02, 2024

                            Lead Product(s) : Testosterone Undecanoate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Lipocine

                            Deal Size : $270.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone Undecanoate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Lipocine

                            Deal Size : $270.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PharmaTher Updates Its Priority Abbreviated New Drug Application for Ketamine

                            Details : Under the agreement, Verity Pharma will market Tlando (testosterone undecanoate), the first and only oral testosterone replacement therapy (TRT), in the United States and, if approved, in Canada.

                            Product Name : Tlando

                            Product Type : Small molecule

                            Upfront Cash : $2.5 million

                            January 18, 2024

                            Lead Product(s) : Testosterone Undecanoate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Lipocine

                            Deal Size : $270.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Granisetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Recipient : Cumberland Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support ...

                            Details : Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.

                            Product Name : Sancuso

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 09, 2022

                            Lead Product(s) : Granisetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Recipient : Cumberland Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Acerus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO...

                            Details : Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activ...

                            Product Name : Natesto

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 10, 2022

                            Lead Product(s) : Testosterone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Acerus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Calmette-Guérin: Strain Russian BCG-I

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Verity Pharmaceuticals Reports that Bladder Cancer Drug Shortage Resolved with Health Canada Approval

                            Details : Verity Pharmaceuticals has received a notice of compliance with conditions (NOC/c) from Health Canada for the VERITY-BCG™ (Bacillus Calmette-Guérin [BCG]: Strain Russian BCG-I).

                            Product Name : VERITY-BCG

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 24, 2021

                            Lead Product(s) : Bacillus Calmette-Guérin: Strain Russian BCG-I

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed

                            Verity Pharmaceuticals Inc

                            Canada arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triptorelin Pamoate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prost...

                            Details : The companies have entered into an exclusive agreement that grants Verity Pharmaceuticals Inc. the rights to commercialize Trelstar® (triptorelin pamoate for injectable suspension), a hormone therapy for patients living with prostate cancer.

                            Product Name : Trelstar

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 09, 2020

                            Lead Product(s) : Triptorelin Pamoate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth